Healthcare
Live Price
Offline$5.80
-2.68% today
1Y Change
+31.32%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vanda Pharmaceuticals Inc. (VNDA) is a Healthcare stock with a market cap of $450.00M and listed on NASDAQ. The stock last traded around $5.80 and up 31.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +8.7%, EPS growth of -1068.8%, a dividend yield of 0.0%. What stands out right now is revenue +8.7%, EPS -1068.8%, free cash flow -579.8% with operating margin -71.6% and ROIC -44.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VNDA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VNDA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VNDA Max Drawdown
-38.60%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VNDA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$268.7M
+5.6% YoY
FY Net Income
$33.2M
+428.3% YoY
Free Cash Flow
$63.7M
+103.4% YoY
Revenue Growth
+8.7%
EPS Growth
-1068.8%
Gross Margin
93.2%
Net Margin
-102.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 216M | 199M | 193M | 254M | 269M |
| Gross Profit | 203M | 187M | 178M | 230M | 243M |
| Operating Income | -151M | -41M | -14M | 6M | 42M |
| EBITDA | -139M | -33M | -11M | 9M | 45M |
| Net Income | -220M | -19M | 3M | 6M | 33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 85M | 102M | 136M | 135M | 52M |
| Total Assets | 489M | 656M | 648M | 634M | 594M |
| Total Liabilities | 162M | 118M | 104M | 107M | 89M |
| Shareholder Equity | 327M | 539M | 545M | 527M | 505M |
| Total Debt | 13M | 12M | 9M | 11M | 12M |
| Net Debt | -72M | -90M | -126M | -124M | -40M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
64M
+100.8% YoY
Capital Expenditures
552K
+18.7% YoY
Free Cash Flow
64M
+103.4% YoY
Key ratios
Gross Margin
93.2%
Operating Margin
-71.6%
Net Margin
-102.0%
ROE
-49.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.